ProShare Advisors
EIDX

ProShare Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

ProShare Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,392
Closed -$1.1M – 2265
2020
Q4 		$1.1M Buy
8,392
+836
+11% +$73.9K ﹤0.01% 837
2020
Q3 		$382K Sell
7,556
-90
-1% -$4.05K ﹤0.01% 1051
2020
Q2 		$364K Buy
7,646
+1,822
+31% +$84.7K ﹤0.01% 1113
2020
Q1 		$285K Sell
5,824
-3,813
-40% -$194K ﹤0.01% 895
2019
Q4 		$553K Sell
9,637
-1,607
-14% -$79.6K ﹤0.01% 1018
2019
Q3 		$404K Sell
11,244
-1,222
-10% -$47.7K ﹤0.01% 1066
2019
Q2 		$387K Sell
12,466
-1,782
-13% -$48.3K ﹤0.01% 1127
2019
Q1 		$334K Buy
14,248
+1,030
+8% +$16.5K ﹤0.01% 1197
2018
Q4 		$182K Buy
+13,218
New +$167K ﹤0.01% 1393

ProShare Advisors's EIDX Position: Q1 2021 in Review

ProShare Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 8,392 shares — an estimated $1.1M sold.

ProShare Advisors first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $1.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • ProShare Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • ProShare Advisors sold 8,392 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.1M.
  • ProShare Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
  • ProShare Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $1.1M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on ProShare Advisors's 13F filing for Q1 2021, filed 14 May 2021.